Tasimelteon: A selective and unique receptor binding profile

Hetlioz® (tasimelteon) is the first approved treatment in the United States for Non-24-Hour Sleep-Wake Disorder (Non-24). We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes...

Full description

Saved in:
Bibliographic Details
Published in:Neuropharmacology 2015-04, Vol.91, p.142-147
Main Authors: Lavedan, Christian, Forsberg, Mark, Gentile, Anthony J.
Format: Article
Language:English
Subjects:
Benzofurans - chemistry
Benzofurans - metabolism
Circadian regulator
Circadian rhythm
Cyclopropanes - chemistry
Cyclopropanes - metabolism
Hetlioz
Humans
Melatonin receptor
Non-24
Protein Binding
Receptors, Melatonin - agonists
Receptors, Melatonin - metabolism
Tasimelteon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hetlioz® (tasimelteon) is the first approved treatment in the United States for Non-24-Hour Sleep-Wake Disorder (Non-24). We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes. Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1–4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO–K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively). Tasimelteon was also shown to have no appreciable affinity for more than 160 other pharmacologically relevant receptors and several enzymes. •Tasimelteon was shown to have full agonist activity at both MT1 and MT2 receptors.•Tasimelteon has greater affinity for the MT2 receptor than for the MT1 receptor.•Tasimelteon has no affinity for other pharmacologically relevant receptors.
ISSN:0028-3908
1873-7064
DOI:10.1016/j.neuropharm.2014.12.004